Nycomed Amersham to buy Molecular Dynamics to create wider portfolio in genetic research
This article was originally published in Clinica
Executive Summary
Nycomed Amersham is to buy the US gene sequencing company, Molecular Dynamics, in a cash deal which values the company at $256 million. It will pay around $199 million for shares it does not already own - it already holds a 10% interest in Molecular.